Alx Oncology Holdings (ALXO) Income towards Parent Company (2019 - 2026)
Alx Oncology Holdings recorded quarterly Income towards Parent Company of -$18.1 million in Q1 2026, up 20.66% quarter-over-quarter from -$22.8 million in Q4 2025, and up 41.08% year-over-year from -$12.8 million in Q1 2025.
Alx Oncology Holdings' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$18.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 41.08% year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at -$89.0 million (up 31.52% YoY), while the FY2025 annual figure was -$101.7 million, up 24.18% from the prior year.
- Income towards Parent Company came in at -$18.1 million for Q1 2026 at Alx Oncology Holdings, up from -$22.8 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $91.1 million in Q4 2023 to a low of -$51.0 million in Q3 2023.
- A 5-year average of -$23.7 million and a median of -$30.6 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company tumbled 1555.03% in 2022 and surged 397.18% in 2023, its largest moves.
- Alx Oncology Holdings' Income towards Parent Company stood at -$30.6 million in 2022, then soared by 397.18% to $91.1 million in 2023, then sank by 132.02% to -$29.2 million in 2024, then advanced by 21.71% to -$22.8 million in 2025, then increased by 20.66% to -$18.1 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$18.1 million, -$22.8 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.12 Mn |
| Dec 31, 2025 | -22.83 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -30.74 Mn |
| Dec 31, 2024 | -29.16 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -39.39 Mn |
| Mar 31, 2024 | -35.57 Mn |
| Dec 31, 2023 | 91.07 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -34.48 Mn |
| Mar 31, 2023 | -30.28 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -35.31 Mn |
| Jun 30, 2022 | -32.92 Mn |
| Mar 31, 2022 | -24.53 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | -24.57 Mn |
| Jun 30, 2021 | -16.27 Mn |
| Mar 31, 2021 | -14.19 Mn |
| Dec 31, 2020 | 17.27 Mn |
| Sep 30, 2020 | -10.18 Mn |
| Jun 30, 2020 | -11.33 Mn |
| Mar 31, 2020 | -5.45 Mn |
| Dec 31, 2019 | -8.58 Mn |
| Sep 30, 2019 | -3.04 Mn |
| Jun 30, 2019 | -4.20 Mn |